![]() There are no restrictions regarding personal contact (visual or physical proximity) with other people after receiving Xofigo. Personal contact and radiation exposure to others: You should report signs of dehydration, hypovolemia, urinary retention, or renal failure / insufficiency to your doctor. It is important to stay well hydrated and to monitor oral intake, fluid status, and urine output while being treated with Xofigo. You should talk to your healthcare provider about any other medications they are currently taking for prostate cancer. Patients using Xofigo have an increase in bone fractures and mortality when used in combination with abiraterone acetate and prednisone/prednisolone. Increased Fractures and Mortality in Combination with Abiraterone plus Prednisone/Prednisolone: You should report signs of bleeding or infections to your health care provider. It is important to be compliant with blood cell count monitoring appointments while receiving Xofigo. Male patients should use condoms and their female partners (of reproductive potential) should use effective contraception during and for 6 months after completing treatment with Xofigo.īased on how Xofigo works it may impair a male's ability to father children if they are of reproductive potential. Male patients should not get female partners pregnant during treatment with Xofigo and for 6 months after stopping treatment. It is important to warn pregnant females and females of reproductive potential of the potential risk to a fetus. Xofigo can cause fetal harm when administered to a pregnant female. The safety and efficacy of Xofigo have not been established in females. This medicine should be discontinued in patients who experience life-threatening complications despite supportive care measures. Monitor patients with compromised bone marrow reserve closely. Discontinue Xofigo if hematologic values do not recover within 6 to 8 weeks after treatment. Warningsīone Marrow Suppression: Blood counts should be measured before the first treatment and also before every dose of Xofigo. Once Xofigo is attached to the bone cancer, it gives off radiation that breaks the DNA of the cancer cells, which kills the prostate cancer cells. Xofigo works as it acts like calcium and goes to areas of bone that are growing quickly, which is where the bone cancer is in the body. Xofigo contains a radioactive ingredient called radium 233 that concentrates in the bone where there is cancer and kills the cancer cells. Xofigo (radium 223 dichloride) is an intravenous injection used for the treatment of prostate cancer when hormonal or surgical treatment that lowers testosterone is no longer working, and the prostate cancer has spread to bones but has not spread to other parts of the body. Medically reviewed by Melisa Puckey, BPharm. Drug class: Therapeutic radiopharmaceuticals
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |